Previous Close | 5.12 |
1-Year Change | -58.61% |
6-Months Change | -60.62% |
3-Months Change | -55.56% |
Moving Avg (50d) | 6.4498 |
Moving Avg (200d) | 11.0209 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 108.3K |
Beta (3-Years) | 1.04 |
Revenue Growth (ttm) | -14.61% |
Net Profit Margin (ttm) | -171.58% |
Return On Assets (ttm) | -30.81% |
EPS (ttm) | -1366.46 |
PE Ratio (ttm) | - |
Dividend Yield | % |
Asset Description: | Enanta Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2025-01-28 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
5.222 | 5.376 | 5.478 | 5.632 | 5.888 | 6.144 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.